How We Think - Opdivo

These are the posts from the How we think section that have been tagged with Opdivo.

To see all tags used in our posts, click here.

Stumble-but-not-a-fall-whats-next-for-opdivo-feature-image

A stumble, but not a fall – what’s next for Opdivo?

Louis Perdios|24th August 2016

In this article, Associate Consultant Louis Perdios talks about the immunotherapy drug Opdivo and the daunting challenges faced by BMS after disappointing results. However the future for Opdivo may not be as bleak as it seems. 

 

read more

immunotherapy-in-oncology-innate-and-adaptive-immunity

Immunotherapy in oncology

David Cooney|27th July 2016

In this article, Consultant David Cooney explores the medical insights, unmet needs, and future of the vastly growing area of immunotherapy as the fourth pillar in oncology.

read more

immunotherapy-perspective-magazine-blood-cells-Blue-Latitude-Health

The special immunotherapy edition of Perspective magazine is live

Blue Latitude Health|19th May 2016

Blue Latitude Health have worked with four of the eight immunotherapies currently approved by the FDA, so we've pooled our expertise across the different capabilities to give you a clear view on the fourth pillar of care in oncology.

read more

The landscape of healthcare has changed. So have we.

Blue Latitude Health is now Fishawack Health

Discover fishawack.com
Redirecting you to fishawack.com in 5...